User login
Key clinical point: First-line palbociclib plus letrozole proved to be a more effective treatment option than letrozole alone in a real-world population of older patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer (BC).
Major finding: Real-world progression-free survival (22.2 vs 15.8 months; adjusted hazard ratio 0.59; P < .001) was significantly prolonged and real-world best tumor response rate was significantly higher (52.4% vs. 22.1%; adjusted odds ratio 2.0; P < .001) in patients receiving palbociclib+letrozole vs letrozole alone.
Study details: Findings are from a retrospective cohort study including 796 women aged ≥65 years with HR+/HER2− metastatic BC who initiated first-line treatment with palbociclib+letrozole or letrozole alone.
Disclosures: This study was sponsored by Pfizer Inc. Three authors declared being employees of and owning stocks in Pfizer Inc. The other authors declared receiving advisory board fees, consulting fees, honoraria, or research funding from Pfizer Inc and other sources.
Source: Rugo HS et al. Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer. Breast. 2023 (Mar 27). Doi: 10.1016/j.breast.2023.03.015
Key clinical point: First-line palbociclib plus letrozole proved to be a more effective treatment option than letrozole alone in a real-world population of older patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer (BC).
Major finding: Real-world progression-free survival (22.2 vs 15.8 months; adjusted hazard ratio 0.59; P < .001) was significantly prolonged and real-world best tumor response rate was significantly higher (52.4% vs. 22.1%; adjusted odds ratio 2.0; P < .001) in patients receiving palbociclib+letrozole vs letrozole alone.
Study details: Findings are from a retrospective cohort study including 796 women aged ≥65 years with HR+/HER2− metastatic BC who initiated first-line treatment with palbociclib+letrozole or letrozole alone.
Disclosures: This study was sponsored by Pfizer Inc. Three authors declared being employees of and owning stocks in Pfizer Inc. The other authors declared receiving advisory board fees, consulting fees, honoraria, or research funding from Pfizer Inc and other sources.
Source: Rugo HS et al. Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer. Breast. 2023 (Mar 27). Doi: 10.1016/j.breast.2023.03.015
Key clinical point: First-line palbociclib plus letrozole proved to be a more effective treatment option than letrozole alone in a real-world population of older patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer (BC).
Major finding: Real-world progression-free survival (22.2 vs 15.8 months; adjusted hazard ratio 0.59; P < .001) was significantly prolonged and real-world best tumor response rate was significantly higher (52.4% vs. 22.1%; adjusted odds ratio 2.0; P < .001) in patients receiving palbociclib+letrozole vs letrozole alone.
Study details: Findings are from a retrospective cohort study including 796 women aged ≥65 years with HR+/HER2− metastatic BC who initiated first-line treatment with palbociclib+letrozole or letrozole alone.
Disclosures: This study was sponsored by Pfizer Inc. Three authors declared being employees of and owning stocks in Pfizer Inc. The other authors declared receiving advisory board fees, consulting fees, honoraria, or research funding from Pfizer Inc and other sources.
Source: Rugo HS et al. Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer. Breast. 2023 (Mar 27). Doi: 10.1016/j.breast.2023.03.015